ARGX-113-2301: A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Efgartigimod PH20 SC Administered by Prefilled Syringe in Adult Participants With Thyroid Eye Disease
- Title
- A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Efgartigimod PH20 SC Administered by Prefilled Syringe in Adult Participants With Thyroid Eye Disease
- Principal Investigator
- Nguyen, John
- Phase
- III
- Age Group
- Adult
- Applicable Disease Sites
- Other
- Participating Institutions
- Eye Institute
- West Virginia University
- Contacts
- Athena Echols
- Clinical Trials Coordinator
- Phone: +1 304-598-6977
- Email: athena.sparks@wvumedicine.org
- Natalie London
- Email: natalie.london@hsc.wvu.edu